SGLT2 inhibitors – reports of Fournier’s gangrene

The MHRA have provided the following advice arising from reports of Fournier’s gangrene (necrotising fasciitis of the genitalia or perineum)  – a rare but serious and potentially life-threatening infection – in association with use of sodium-glucose co-transporter 2 (SGLT2) inhibitors:

• if Fournier’s gangrene is suspected, stop the SGLT2 inhibitor and urgently start treatment (including antibiotics and surgical debridement as required)
• urogenital infection or perineal abscess may precede necrotising fasciitis
• advise patients to seek urgent medical attention if they experience severe pain, tenderness, erythema, or swelling in the genital or perineal area, accompanied by fever or malaise